Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.
Christian F. Singer(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Florian Fitzal, Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Martin Filipits(University of Vienna), Guenther G. Steger(Mount Vernon Hospital), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Sophie Frantal(Statistics Austria), Georg Pfeiler(Medical University of Vienna), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), Viktor Wette, Christoph Suppan(Medical University of Graz), Muy‐Kheng M. Tea(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k